Compare MIN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIN | TENX |
|---|---|---|
| Founded | 1988 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.8M | 317.8M |
| IPO Year | N/A | 2001 |
| Metric | MIN | TENX |
|---|---|---|
| Price | $2.45 | $10.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 148.2K | ★ 596.0K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.41 | $5.34 |
| 52 Week High | $2.72 | $18.38 |
| Indicator | MIN | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 33.52 |
| Support Level | $2.41 | $6.40 |
| Resistance Level | $2.52 | $14.15 |
| Average True Range (ATR) | 0.02 | 0.64 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 42.86 | 8.40 |
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.